Bibliographic Details
| Title: |
Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists. |
| Authors: |
Albanese, A., Colosimo, C. |
| Source: |
Acta Neurologica Scandinavica. May2003, Vol. 107 Issue 5, p349-355. 7p. |
| Subjects: |
Dopamine agonists, Parkinson's disease, Bromocriptine, Symptoms, Dopamine receptors, Antidepressants |
| Abstract: |
The present paper reviews clinical studies on the use of dihydroergocriptine (DHEC), an ergot derivative with dopamine agonist activity, for the treatment of Parkinson's disease. This compound is a hydrogenated ergot derivative structurally quite similar to bromocriptine, from which it differs because of the hydrogenation in C9 –C10 and the lack of bromine in C2 . DHEC has a potent D2-like receptor agonist and a partial D1-like receptor agonist activity; because of this biochemical profile, it has been suggested that DHEC may produce fewer side-effects and have clinical efficacy equal to that of a classical dopamine agonist. Several open-label and double-blind studies indicate that DHEC is an efficacious remedy for parkinsonian signs and symptoms. Further studies are necessary to compare DHEC to new dopamine agonists (pergolide, cabergoline, ropinirole, and pramipexole) which have been more recently marketed. [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Psychology and Behavioral Sciences Collection |
